Sulindac sulfone is most effective in modulating β-catenin-mediated transcription in cells with mutant APC

Annals of the New York Academy of Sciences

Volumn 1059, Issue , 2005, Pages 41-55

  Chang, Wen Chi L ^a   Everley, Lynette C ^a   Pfeiffer II, Gordon R ^a   Cooper, Harry S ^a   Barusevicius, Alan ^a,b   Clapper, Margie L ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b MDR Global Systems LLC   (United States)

Author keywords

APC; Colon; Sulindac sulfone; catenin

Indexed keywords

APC PROTEIN; AZOXYMETHANE; BETA CATENIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEASOME INHIBITOR; SULINDAC SULFIDE; SULINDAC SULFONE;

ADENOMATOUS POLYP; ANIMAL EXPERIMENT; ANIMAL MODEL; COLON CANCER; COLON CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN;

ANIMALIA;

EID: 32244442175     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1339.020     Document Type: Conference Paper

References (37)

1. COTTRELL, S., D. BICKNELL, L. KAKLAMANIS, et al. 1992. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 340: 626-630.
2. POLAKIS, P. 1997. The adenomatous polyposis coli (APC) tumor suppressor. Biochim. Biophys. Acta 1332: F127-F147.
3. RUBINFELD, B., B. SOUZA, I. ALBERT, et al. 1993. Association of the APC gene product with β-catenin. Science 262: 1731-1734.
4. SU, L.K., B. VOGELSTEIN & K.W. KINZLER. 1993. Association of the APC tumor suppressor protein with catenins. Science 262: 1734-1737.
5. KORINEK, V., N. BARKER, P.J. MORIN, et al. 1997. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784-1787.
6. SHTUTMAN, M., J. ZHURINSKY, I. SIMCHA, et al. 1999. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96: 5522-5527.
7. HE, T.-C., A.B. SPARKS, C. RAGO, et al. 1998. Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
8. HE, T.C., T.A. CHAN, B. VOGELSTEIN, et al. 1999. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.
9. INOMATA, M., A. OCHIAI, S. AKIMOTO, et al. 1996. Alteration of β-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res. 56: 2213-2217.
10. SPARKS, A.B., P.J. MORIN, B. VOGELSTEIN, et al. 1998. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58: 1130-1134.
11. MOORGHEN, M., P. INCE, K.J. FINNEY, et al. 1988. A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J. Pathol. 156: 341-347.
12. SKINNER, S.A., A.G. PENNEY & P.E. O'BRIEN. 1991. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch. Surg. 126: 1094-1096.
13. LABAYLE, D., D. FISCHER, P. VIELH, et al. 1991. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639.
14. GIARDIELLO, P.M., S.R. HAMILTON, A.J. KRUSH, et al. 1993. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328: 1313-1316.
15. PIAZZA, G.A., A.K. RAHM, T.S. FINN, et al. 1997. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57: 2452-2459.
16. PIAZZA, G.A., D.S. ALBERTS, L.J. HIXSON, et al. 1997. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57: 2909-2915.
17. REDDY, B.S., T. KAWAMORI, R.A. LUBET, et al. 1999. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res. 59: 3387-3391.
18. VAN STOLK, R., G. STONER, W.L. HAYTON, et al. 2000. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin. Cancer Res. 6: 78-89.
19. SCHNITZLER, M., T. DWIGHT & B.C. ROBINSON. 1996. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study. Gut 38: 707-713.
20. MORIN, P.J., B. VOGELSTEIN & K.W. KINZLER. 1996. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA 93: 7950-7954.
21. ILYAS, M., I.P.M. TOMLINSON, A. ROWAN, et al. 1997. β-catenin mutations in cell lines established from human colorectal cancers. Proc. Natl. Acad. Sci. USA 94: 10330-10334.
22. HIXSON, L., D.S. ALBERTS, M. KRUTZSCH, et al. 1994. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol. Biomarkers Prev. 3: 433-437.
23. ALBERTS, D.S., L. HIXSON, D. AHNEN, et al. 1995. Do non-steroidal anti-inflammatory drugs (NSAIDs) exert their colon cancer chemoprevention activities through inhibition of colonic mucosal prostaglandin synthetase? J. Cell. Biochem. Suppl. 22: 18-23.
24. LIM, J.T., G.A. PIAZZA, E.K. HAN, et al. 1999. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol. 58: 1097-1107.
25. PIAZZA, G., A. RAHM, R. PAMUKCU, et al. 1996. Induction of apoptosis by sulindac metabolites involves a p53 and bcl-2 independent mechanism and does not require cell cycle arrest. Gastroenterology 110: A577.
26. Li, H., L. LIU, M.L. DAVID, et al. 2002. Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem. Pharmacol. 64: 1325-1336.
27. THOMPSON, W.J., G.A. PIAZZA, H. LI, et al. 2000. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 60: 3338-3342.
28. RUBINFELD, B., I. ALBERT, E. PORFIRI, et al. 1996. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science 272: 1023-1026.
29. SHIOZAKI, H., T. KADOWAKI, Y. DOKI, et al. 1995. Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br. J. Cancer. 71: 250-258.
30. OCHIAI, A., S. AKIMOTO, Y. KANAI, et al. 1994. c-erbB-2 gene product associates with catenins in human cancer cells. Biochem. Biophys. Res. Commun. 205: 73-78.
31. MORIN, P.J., A.B. SPARKS, V. KORINEK, et al. 1997. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275: 1787-1790.
32. DIEHL, J.A., M. CHENG, M.F. ROUSSEL, et al. 1998. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12: 3499-3511.
33. SHAO, J., H. SHENG, H. INOUE, et al. 2000. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. 275: 33951-33956.
34. WILLIAMS, C.S., A.P. GOLDMAN, H. SHENG, et al. 1999. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia 1: 170-176.
35. WATANABE, M., H. KAKIUCHI, H. KATO, et al. 1996. APC gene mutations in human prostate cancer. Jpn. J. Clin. Oncol. 26: 77-81.
36. VOELLER, H.J., C.I. TRUICA & E.P. GELMANN. 1998. β-Catenin mutations in human prostate cancer. Cancer Res. 58: 2520-2523.
37. REDSTON, M., K.L. NATHANSON, Z.Q. YUAN, et al. 1998. The APCI1307K allele and breast cancer risk. Nat. Genet. 20: 13-14.